Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 5/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365379 | 0.92 | HDAC2 (0.44) | MCHR1HDAC2 | |
| SCHEMBL19670240 | 0.87 | PRMT5 (0.37) | HDAC2MAP4K4 | |
| SCHEMBL19365429 | 0.87 | POLB (0.36) | MCHR1HDAC2SCN10AMAP4K4CYP11B2 | |
| SCHEMBL19365728 | 0.86 | HDAC2 (0.43) | HDAC2ABL1DYRK1A | |
| SCHEMBL19365727 | 0.85 | ATM (0.37) | MCHR1ABL1 | |
| SCHEMBL19365702 | 0.85 | SCN10A (0.34) | HDAC2SCN10ADYRK1AMAP4K4CTPS1 | |
| SCHEMBL19670535 | 0.84 | GSK3B (0.38) | MCHR1HDAC2GSK3BDYRK1ACPT1A | |
| SCHEMBL19365331 | 0.83 | HDAC2 (0.37) | HDAC2ABL1GSK3BMAP4K4 | |
| SCHEMBL19670520 | 0.83 | CPT1A (0.37) | MCHR1HDAC2GSK3BDYRK1ACPT1A | |
| SCHEMBL19706241 | 0.82 | HDAC2 (0.35) | MCHR1HDAC2GSK3BDYRK1ACPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MCHR1 4256/4885HDAC2 50/4885ABL1 4089/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | MCHR1 4256/4885HDAC2 50/4885ABL1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.